Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14914294 | 0.80 | ALDH1A1 (0.38) | ALDH1A1POLBLMNAKMT2AF2RL3 | |
| SCHEMBL12179656 | 0.78 | ALDH1A1 (0.37) | ALDH1A1POLBLMNATDP1MAPT | |
| SCHEMBL3750648 | 0.77 | F2RL3 (0.40) | ALDH1A1LMNATDP1MAPTKMT2A | |
| SCHEMBL12179475 | 0.77 | CYP1A2 (0.43) | ALDH1A1LMNAMAPTKMT2AF2 | |
| SCHEMBL2475555 | 0.76 | F2 (0.44) | ALDH1A1POLBLMNAMAPTKMT2A | |
| SCHEMBL3644933 | 0.74 | MAPT (0.44) | ALDH1A1LMNATDP1MAPTKMT2A | |
| SCHEMBL2471752 | 0.74 | MEN1 (0.41) | ALDH1A1POLBLMNAMAPTKMT2A | |
| SCHEMBL2474307 | 0.72 | F2RL3 (0.38) | ALDH1A1POLBLMNAMAPTKMT2A | |
| SCHEMBL3682420 | 0.71 | ALDH1A1 (0.39) | ALDH1A1LMNATDP1MAPTKMT2A | |
| SCHEMBL12196584 | 0.71 | ALDH1A1 (0.35) | ALDH1A1POLBLMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | PNPO, CYP4B1, DPYD | ALDH1A1 488/4885POLB 1848/4885LMNA 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.